« Previous
Next »
Titles
- 2006 Medicare Advantage benefits and premiums1
- Abuse-deterrent formulations of opioids: effectiveness and value : final evidence report1
- Calculation of potential inflation-indexed rebates for Medicare Part B drugs1
- California employer health benefits: workers shoulder more costs1
- Drug discount program: update on agency efforts to improve 340B program oversight : testimony before the Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, House of Representatives1
- Excluding noncovered versions when setting payment for two Part B drugs would have resulted in lower drug costs for Medicare and its beneficiaries1
- Impact of Medicare Advantage prescription drug plan star ratings on enrollment before and after implementation of quality-related bonus payments in 20121
- Indication-specific pricing of pharmaceuticals in the United States health care system: a report from the 2015 ICER Membership Policy Summit1
- Medicare Part D and the financial protection of the elderly1
- Medicare Part D: a first look at prescription drug plans in 20191
- Part D plans generally include drugs commonly used by dual eligibles: 20191
- Prescription drugs in Nebraska: a survey of experiences and opinions1
- Reducing wasteful spending in employers' pharmacy benefit plans1
- Short-term limited duration plans and HIV1
- State Pharmacy Assistance Programs vs. Medicare prescription drug plans: how do they contain rising costs?1
- Strategic analysis & intelligence (SAI) report: the tier 4 phenomenon : shifting the high cost of drugs to consumers1
- The Medicare drug benefit coverage gap: the basics1
- The share of people with high medical costs increased prior to implementation of the Affordable Care Act1
- Top spenders among commercially-insured: increased spending concentration and consistent turnover from 2013 to 20151